Estados financieros detallados de Metagenomi, Inc. Common Stock (MGX): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto 74.3%, margen operativo -7.4%, margen neto -6.9%.
Al precio actual de $1.15, MGX presenta beneficios negativos (P/E no significativo) y un ROE del -63.65%. La capitalización bursátil es de $43M.
Cuenta de Resultados (10 años)
| Año | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Ingresos | $243000 | $17.2M | $44.8M | $52.3M | $25.2M |
| Coste de Ventas | $387000 | $1.7M | $94.4M | 0 | $5.3M |
| Beneficio Bruto | -$144000 | $15.5M | -$49.6M | $52.3M | $19.9M |
| I+D | $14.5M | $43.1M | $94.4M | $109.2M | $94.4M |
| Generales y Administrativos | $9.7M | $18.7M | $28.8M | $32.0M | $26.8M |
| Gastos Operativos | $23.8M | $60.1M | $28.8M | $141.2M | $115.9M |
| Beneficio Operativo | -$23.9M | -$44.6M | -$78.5M | -$88.9M | -$96.0M |
| EBITDA | -$20.8M | -$39.2M | -$56.0M | -$78.2M | -$82.6M |
| Gastos por Intereses | $302000 | $98000 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$21.4M | -$41.0M | -$60.2M | -$83.6M | -$87.9M |
| Impuestos | 0 | $2.6M | $8.0M | -$5.5M | -$58000 |
| Beneficio Neto | -$21.4M | -$43.6M | -$68.3M | -$78.1M | -$87.9M |
| BPA | $-3.62 | $-1.16 | $-1.82 | $-2.09 | $-2.36 |
| BPA Diluido | $-3.62 | $-1.16 | $-1.82 | $-2.09 | $-2.36 |
| Acciones en Circulación (Diluidas) | $5.9M | $37.5M | $37.5M | $37.4M | $37.3M |
Cuenta de Resultados (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Ingresos | $8.7M | $3.9M | $1.2M | -$257000 |
| Beneficio Bruto | $7.3M | $2.6M | $385000 | -$257000 |
| Beneficio Operativo | -$22.8M | -$24.4M | -$24.6M | -$28.8M |
| EBITDA | -$19.3M | -$21.2M | -$21.8M | -$26.2M |
| Beneficio Neto | -$20.4M | -$22.5M | -$23.1M | -$27.5M |
| BPA | $-0.55 | $-0.60 | $-0.61 | $-0.73 |
| BPA Diluido | $-0.55 | $-0.60 | $-0.61 | $-0.73 |
Balance (10 años)
| Año | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Caja y Equivalentes | $39.3M | $184.4M | $140.6M | $27.4M | $41.7M |
| Inversiones a Corto | $68.9M | $177.7M | $130.6M | $220.9M | $119.1M |
| Cuentas por Cobrar | $490000 | $1.3M | $2.5M | $1.3M | $305000 |
| Inventario | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $108.9M | $366.9M | $278.3M | $258.0M | $165.5M |
| Inmovilizado Material | $22.1M | $33.3M | $65.2M | $57.7M | $47.4M |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $142.0M | $414.5M | $364.8M | $324.6M | $221.1M |
| Cuentas por Pagar | $1.4M | $2.0M | $1.8M | $533000 | $1.5M |
| Deuda a Corto | 0 | 0 | 0 | 0 | 0 |
| Pasivos Corrientes | $25.2M | $48.5M | $68.9M | $37.3M | $22.9M |
| Deuda a Largo | $30.3M | 0 | 0 | 0 | 0 |
| Pasivos Totales | $174.5M | $488.9M | $500.4M | $89.7M | $62.5M |
| Reservas | -$33.1M | -$76.7M | -$144.9M | -$223.0M | -$310.9M |
| Patrimonio Neto | -$32.5M | -$74.4M | -$135.6M | $234.9M | $158.6M |
| Deuda Total | $48.9M | $18.6M | $48.2M | $45.8M | $40.7M |
| Deuda Neta | -$59.2M | -$343.6M | -$223.0M | -$202.5M | -$120.1M |
| Capital Circulante | $83.7M | $318.4M | $209.4M | $220.7M | $142.6M |
Balance (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Caja y Equivalentes | $32.8M | $41.7M | $25.3M | $39.0M |
| Activos Totales | $247.9M | $221.1M | $197.0M | $173.7M |
| Pasivos Totales | $69.5M | $62.5M | $59.2M | $61.1M |
| Patrimonio Neto | $178.4M | $158.6M | $137.8M | $112.6M |
| Deuda Total | $41.7M | $40.7M | $39.2M | $37.7M |
Flujo de Caja (10 años)
| Año | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Beneficio Neto | -$21.4M | -$43.6M | -$68.3M | -$78.1M | -$87.9M |
| Amortizaciones | $387000 | $1.7M | $4.2M | $5.4M | $5.3M |
| Compensación en Acciones | $375000 | $2.0M | $6.9M | $16.2M | $11.9M |
| Cambio en Capital Circulante | $46.3M | $69.5M | -$26.4M | -$59.7M | -$22.1M |
| Flujo de Caja Operativo | $24.3M | $29.7M | -$91.4M | -$109.1M | -$88.9M |
| Inversiones (CapEx) | -$2.9M | -$14.0M | -$9.8M | -$3.1M | -$574000 |
| Adquisiciones | 0 | 0 | 0 | 0 | $37000 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | $21.4M | $15.7M | -$101.2M | -$112.2M | -$89.5M |
Flujo de Caja (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Flujo de Caja Operativo | -$21.3M | -$23.5M | -$21.2M | -$19.5M |
| Inversiones (CapEx) | -$74000 | -$85000 | -$25000 | -$125000 |
| Flujo de Caja Libre | -$21.3M | -$23.6M | -$21.2M | -$19.6M |
| Dividendos Pagados | 0 | 0 | 0 | 0 |
| Compensación en Acciones | $3.0M | $2.7M | $2.6M | $2.3M |
Crecimiento y Márgenes (10 años)
| Año | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Crecimiento Ingresos (anual) | | +6978.2% | +160.2% | +16.8% | -51.8% |
| Crecimiento Beneficio Neto (anual) | | -103.3% | -56.6% | -14.4% | -12.6% |
| Crecimiento BPA (anual) | | +68.0% | -56.9% | -14.8% | -12.9% |
| Cambio en Acciones (anual) | | +531.9% | +0.0% | -0.1% | -0.4% |
| Crecimiento FCF (anual) | | -26.3% | -742.8% | -10.8% | +20.3% |
| Margen Bruto | -59.3% | 89.9% | -110.9% | 100.0% | 78.9% |
| Margen Operativo | -9854.7% | -259.5% | -175.4% | -170.0% | -380.9% |
| Margen EBITDA | -8540.3% | -227.9% | -125.2% | -149.5% | -327.7% |
| Margen Neto | -8823.9% | -253.4% | -152.5% | -149.3% | -348.5% |
| Margen FCF | 8787.7% | 91.6% | -226.2% | -214.5% | -354.9% |
| Tasa Impositiva Efectiva | -0.0% | -6.3% | -13.3% | 6.6% | 0.1% |
Datos por Acción (10 años)
| Año | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| FCF por Acción | $3.60 | $0.42 | $-2.70 | $-3.00 | $-2.40 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $5.9M | $37.5M | $37.5M | $37.4M | $37.3M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -63.65% |
| Rentabilidad sobre capital invertido | -65.88% |
| Rentabilidad sobre activos | -53.81% |
| Margen bruto | 74.29% |
| Margen operativo | -741.58% |
| Margen neto | -689.20% |
Salud financiera
| Deuda / Patrimonio | 0.34 |
| Ratio corriente | 4.50 |
Ratios Clave (10 años)
| Año | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| P/E | -2.85 | -8.89 | -5.66 | -1.73 | -0.69 |
| P/VC | -1.88 | -5.19 | -2.85 | 0.58 | 0.38 |
| P/V | 251.58 | 22.46 | 8.63 | 2.58 | 2.39 |
| Margen Bruto | -59.3% | 89.9% | -110.9% | 100.0% | 78.9% |
| Margen Operativo | -9854.7% | -259.5% | -175.4% | -170.0% | -380.9% |
| Margen Neto | -8823.9% | -253.4% | -152.5% | -149.3% | -348.5% |